This document provides information on heart failure, including:
1. It defines heart failure as the inability of the heart to pump an adequate amount of blood to meet the body's needs.
2. It describes compensatory mechanisms the body uses in response to heart failure like increasing sympathetic activity and activating the renin-angiotensin system.
3. It discusses treatments for heart failure like diuretics, ACE inhibitors, beta-blockers, and cardiac glycosides which aim to reduce workload on the heart and improve contractility.
Coronary artery Disease [CAD] is the most common , serious, chronic life threatening diseases in the USA.
More than 11 million Persons have CAD in USA.
Myocardial Ischemia [Reduced blood & oxygen supply to Heart Muscle ], Caused by
Lack of oxygen due to Inadequate perfusion which result from an Imbalance
Between oxygen supply & Demand.
Coronary artery Disease [CAD] is the most common , serious, chronic life threatening diseases in the USA.
More than 11 million Persons have CAD in USA.
Myocardial Ischemia [Reduced blood & oxygen supply to Heart Muscle ], Caused by
Lack of oxygen due to Inadequate perfusion which result from an Imbalance
Between oxygen supply & Demand.
Heart Failure (Dr Vosik Presentation) Symposia presented in Milot, Haiti at Hôpital Sacré Coeur.
CRUDEM’s Education Committee (a subcommittee of the Board of Directors) sponsors one-week medical symposia on specific medical topics, i.e. diabetes, infectious disease. The classes are held at Hôpital Sacré Coeur and doctors and nurses come from all over Haiti to attend.
This presentation gives you a brief, understandable, captivating and presentable idea on the physiology of blood pressure regulation both on hypertension and hypotension cases.
The file gives the information of Cardiac Failure. Etiology of cardiac failure, types, stages of cardiac failure. It also covers the multisystem effects of cardiac failure, classification of drugs acting on cardiac failure.
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
Normal Labour/ Stages of Labour/ Mechanism of LabourWasim Ak
Normal labor is also termed spontaneous labor, defined as the natural physiological process through which the fetus, placenta, and membranes are expelled from the uterus through the birth canal at term (37 to 42 weeks
Acetabularia Information For Class 9 .docxvaibhavrinwa19
Acetabularia acetabulum is a single-celled green alga that in its vegetative state is morphologically differentiated into a basal rhizoid and an axially elongated stalk, which bears whorls of branching hairs. The single diploid nucleus resides in the rhizoid.
Biological screening of herbal drugs: Introduction and Need for
Phyto-Pharmacological Screening, New Strategies for evaluating
Natural Products, In vitro evaluation techniques for Antioxidants, Antimicrobial and Anticancer drugs. In vivo evaluation techniques
for Anti-inflammatory, Antiulcer, Anticancer, Wound healing, Antidiabetic, Hepatoprotective, Cardio protective, Diuretics and
Antifertility, Toxicity studies as per OECD guidelines
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Macroeconomics- Movie Location
This will be used as part of your Personal Professional Portfolio once graded.
Objective:
Prepare a presentation or a paper using research, basic comparative analysis, data organization and application of economic information. You will make an informed assessment of an economic climate outside of the United States to accomplish an entertainment industry objective.
Safalta Digital marketing institute in Noida, provide complete applications that encompass a huge range of virtual advertising and marketing additives, which includes search engine optimization, virtual communication advertising, pay-per-click on marketing, content material advertising, internet analytics, and greater. These university courses are designed for students who possess a comprehensive understanding of virtual marketing strategies and attributes.Safalta Digital Marketing Institute in Noida is a first choice for young individuals or students who are looking to start their careers in the field of digital advertising. The institute gives specialized courses designed and certification.
for beginners, providing thorough training in areas such as SEO, digital communication marketing, and PPC training in Noida. After finishing the program, students receive the certifications recognised by top different universitie, setting a strong foundation for a successful career in digital marketing.
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
2. INTRODUCTION
• Inability of the heart to pump an
adequate amount of blood to the
body’s needs
• CO is inadequate to provide oxygen
needed by peripheral tissues
3. AFTERLOAD AND PRELAOD
• Afterload is the tension or stress
developed in the wall of the left ventricle
during ejection
• Preload is the stretch exerted on the
muscle in the resting state. (diastolic
phase.)
7. CAUSES OF HEART
FAILURE
• Hypertension
• Prolonged Alcohol or Drug Addiction
• Previous Heart Attack
• Chronic Rapid Heart Beats
8. SYMPTOMS OF HEART FAILURE
• Edema of the
bronchial mucosa
• Pulmonary edema
• Cardiomegaly
• Edema in other body
parts
• Tachycardia
• Coughing
• Dyspnea
• Fatigue
10. SYSTOLIC DYSFUNCTION (FORWARD
FAILURE)
• Inadequate force is generated to eject blood
normally
• Reduce cardiac output, ejection fraction (< 45%)
Typical of acute heart failure
• Responsive to inotropics
11. DIASTOLIC DYSFUNCTION (BACKWARD
FAILURE)
• Inadequate relaxation to permit normal filling
• Hypertrophy and stiffening of myocardium
• Cardiac output may be reduced
• Ejection fraction is normal
• Do not respond optimally to inotropic agents
12.
13. HIGH OUTPUT FAILURE
• Increase demand of the body with insufficient
cardiac output
• Hyperthyroidism, beri-beri, anemia, AV shunts
• Treatment is correction of underlying cause
14. ACUTE HEART FAILURE
• Sudden development of a large myocardial
infarction or rupture of a cardiac valve in a patient
who previously was entirely well, usually
predominant systolic dysfunction
15. CHRONIC HEART FAILURE
• Typically observed in patients with dilated
cardiomyopathy or multivalvular heart diseases
that develops or progresses slowly
16. COMPENSATORY MECHANISMS OF
BODY DURING HEART FAILURE
• Three types of compensatory mechanisms
2. Neuronal Responses
3. Neuro-endocrinal system
4. Autoregulatory systems
17. Neuronal Responses
• Baroreceptors in the vascular system detect decrease in
BP
• Enhanced sympathetic outflow to the heart and to
peripheral vasculature
• Individual feeling status will also increase sympathetic
system
• Results in release of nor adrenaline and catecholamines
which increase heart rate and redistribution of blood to
vital organs
• Kidney will also help by retention of water and
electrolytes
•
18. Neuro-endocrinal system
• Reduced blood pressure will Stimulate the renin
angiotensin system
• Reduced blood supply to kidney lead to secretion of
renin
• Production of angiotensin II
• Retention of water and electrolyte
• Less oxygen supply to kidney enhances production of
erythropoetin which increases RBC’s production
20. Autoregulatory systems
• Neuronal structures of heart capable of secreting
catecholamines due to anoximia
• Self stimulation of heart muscle called as catecholamine
heart drive
• Do not work during congestive heart failure
22. AUTOREGULATORY MECHANISMS
Atrial pressure
Oxygen supply
Tachycardia
Self Stimulation of heart
muscle
Atrio-peptide
releases
Release of catecholamine
Relaxation of
blood vessels Heart rate
Compensatory
mechanism
23. STRATEGIES FOR CHF
• Increase cardiac contractility
• Decrease preload ( left ventricular pressure)
• Decrease after load (systemic vascular resistance)
• Normalize heart rate and rhythm
24. REDUCE WORK LOAD OF HEART
1.Adjustment of heart rate(AV and SA nodal blocking agents)
2. Restrict sodium (low salt diet)
3. Give diuretics (removal of retained salt and water)
4. Give angiotensin-converting enzyme inhibitors
(decreases afterload and retained salt and water)
5. Give digitalis (positive inotropic effect on depressed heart)
6. Give vasodilators (decreases preload & afterload)
25. STRATEGIES TO TREAT CHF
Factor Mechanism Therapeutic Strategy
1. Preload (work or stress increased blood volume -salt restriction
the heart faces at the end of and increased venous -diuretic therapy
diastole) tone--->atrial filling -venodilator drugs
2. After load (resistance pressure sympathetic
increased - arteriolar vasodilators
against which the heart stimulation & activation of -decreased angiotensin II
must pump) renin-angiotensin system (ACE inhibitors)
---> vascular resistance --->
increased BP
3. Contractility decreased myocardial -inotropic drugs (cardiac
contractility ---> decreased glycosides)
CO
4. Heart Rate decreased contractility and
decreased stroke volume ---
> increased HR (via
activation of b
adrenoceptors)
26. CLASSIFICATION OF DRUGS USE TO
TRAET CONGESTIVE HEART FAILURE
• Drugs improving force of cardiac contractility(postive
ionotropic)
• Drugs improving compensatory stresses upon the
cardiac performance
27. Drugs improving force of cardiac
contractility(positive ionotropic)
• Cardiac glycosides (digoxin,digitoxin)
• Phospho-di-estrase inhibitors (Inamrinone)
• Beta I agonists(dobutamine)
28. Drugs improving compensatory stresses
upon the cardiac performance
• Diuretics(Thaizides)
• Vasodilators(diazoxide,minoxidil)
• ACE Inhibitors(captopril,inapril)
• Angiotensin II receptor inhibitor(losartan,candisartan)
• Beta-blockers (atinolol,propranol)
29. CARDIAC GLYCOSIDES
• Stimulates myocardial contractility(+ inotropic)
• Improves ventricular emptying
• Increase cardiac output
• Augments ejection fraction
• Promotes diuresis so lowers blood volume.
• Reduce cardiac size
• Used in acute congestive HF
• Not used with diuretics
• Reduces pace maker conduction by stimulating vegal
nerve
30. PHOSPHO-DI-ESTRASE ENZYME
INHIBITORS(INAMRINONE,MILRENONE)
• Increase CAMP and CGMP levels that activates IP3
• These enzymes inhibitors increase cytosolic ca level
• Alter intracellular SR calcium
• Increase cardiac contractility(positive ionotropic effect)
• Cause vasodilatation
• Reduce preload
• Used in acute or refractory HF
31. Beta I agonists
• Stimulate cardiac muscles for rapid contractility
• Increase cardiac output with decrease ventricular filling
pressure
• Used in last stages when patients is in ICU in proper
monitoring
• Used to keep alive the patients at last stages
32. DIURETICS(THIZIDES)
• Increase water secretion from kidney
• Decrease blood volume
• Redude oedema
• Decrease venous return(reduce oxygen demand)
• Reduce cardiac size
• Decrease ventricular pre load
• Improve cardiac efficiency
• E.g Spironolactone
• Aldosterone receptors inhibitors
• Aldosterone cause myocardial and vascular fibrosis and baro-
receptors dysfunctioning
• Beneficial in patients receiving ACE inhibitors
34. ACE INHIBITORS
• Inhibits ACE
• Reduce TPR
• Reduce blood volume
• Reduce sodium water retention by inhibiting aldosterone
• Reduce after load and some how preload
• Reduction in sympathetic outflow
• Excellent drug for long term remodeling of heart and
blood vessels
36. BETA-
BLOCKER(atinolol,propranalol)
• Blocks beta I receptors on heart
• Relax cardiac muscle by reducing cardiac work
• Save from extra heart muscle exercise
• Used in long term therapy
37. CARDIAC GLYCOSIDES
• Also called as cardinolides.
• In 1875 William Withering wrote a treatise on Digitalis.
• It was considered essential in the treatment of CHF.
• It is used in chronic CHF. with chronic atrial fabriliation.
• It is still extremely favoured drug.
39. ADVANTAGES:
• It has two main advantages
2. It is an inotropic agent ( increases myocardial
contractility)
3. It can be administered orally.
40. DISADVANTAGES:
• Its therapeutic index is low.
• Its correct dose, correct therapeutic blood level ranges
are uncertain.
• It has many interactions.
41. CHEMISTRY:
• Molecule consisting of
2. A CPP ring
3. Sugar
4. Lactone
• CCP ring + Lactone together is called Aglycon
46. ABSORPTION
• Digoxin is less lipid soluble than Digitoxin
• Digitoxin completely absorbed after oral administration
• Digoxin can be converted to ineffective agent by bacteria
of gut flora
• Half life of digoxin is 1.5 days
• Half life if digitoxin is 5 days
47. METABOLISM
• Therapeutic window of digoxin is narrow
• Metabolized by liver microsomal enzymes
• Digitoxin is converted to inactive products
• Digitoxin is converted into digoxin after hydroxylation of
digitoxin
• Digoxin level should be measured in patients receiving
this drug
51. FACTORS FACILLATING TOXICITY
• Depletion of serum potassium level
• Concomitant use of drugs
• Presence of renal failure
• Hypothyroidism
• Old age
54. CARDIAC GLYCOSIDES
• MODE OF ACTION:
• Direct Effect on Myocardial contractility, and
electrophysiological properties and also has
vagomimetic effect
• Force of contraction:
• Dose dependent increase in force of contraction in
failing heart – positive ionotropic effect
• Systole is shortened and prolonged diastole
• Contracts more forcefully when subjected to
increased resistance
• Increase in cardiac output – complete emptying of
failed and dilated heart
• Tone:
• Decrease end diastolic size of failing ventricle
• Reduction in oxygen consumption
55. Contd. ---
• Rate and Conduction:
1. Bradycardia
2. Slowing of impulse generation (SAN)
3. Delay of conductivity of AVN
• Direct depressant action on SA and AV nodes
(extravagal)
• Increase in vagal tone:
• Is due to improvement in circulation
• Also due to direct stimulation in vagal center,
sensitization of baroreceptors and sensitization of SA
node to Ach
58. EFFECTS ON HEART
• Increases force of myocardial contraction
• Heart size
• Ejection fraction
• Refractory period in AV node and bundle of hiss
• Number and irregularity of ventricular contraction
59. VAGAL EFFECTS
• Vagal effects at early stages when there is minimum
therapeutic value
• Slowed down the activity of pace maker
• Relaxation phase
• Ejection fraction
60. PHOSPHODIESTRASE INHIBITORS
• Mechanism of Action
• inhibition of type III phosphodiesterase
↑ intracellular cAMP
↑ activation of protein kinase A
o Ca2+ entry through L type Ca channels
• ↑ cardiac output
• ↓ peripheral vascular resistance
61. BETA I AGONIST
Mechanism of Action:
Stimulation of cardiac β1−adrenoceptors: ↑
inotropy > ↑ chromotropy
peripheral vasodilatation
62. ACE INHIBITORS
• Mechanism of Action:
• Afterload reduction
• Preload reduction
• Reduction of facilitation of sympathetic nervous system
• Reduction of cardiac hypertrophy
63. BETA BLOCKERS
• Mechanism of Action:
• influences in the heart (tachycardia, arrhythmias,
remodeling)
• Reduction in damaging sympathetic inhibition of renin
release
64. DIURETICS
• Mechanism of Action:
• Preload reduction: reduction of excess plasma volume
and edema fluid
• After load reduction: lowered blood pressure
• Reduction of facilitation of sympathetic nervous system
65. VASODILATORS
• MODE OF ACTION:
• Reduction in preload through venodilatation or
reduction in afterload through arteriolar dilation or
both